 ?您的位置：對(duì)照品 > 標(biāo)準(zhǔn)品 > 歐洲藥典標(biāo)準(zhǔn)品 > |
|
|
|
| 產(chǎn)品基本信息 |
|
| 產(chǎn)品編號(hào)：A010625 |
| 產(chǎn)品名稱：(R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-2-((4-methylquinazolin-2-yl)netho |
| 產(chǎn)品CAS： |
| 規(guī)格含量：10mg |
| 產(chǎn)品價(jià)格：面議 |
| 聯(lián)系我們: |
 |
|
 |
|
|
| 產(chǎn)品詳細(xì)介紹 |
| 標(biāo)準(zhǔn)品編號(hào): |
A010625 |
| 名稱: |
(R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-2-((4-methylquinazolin-2-yl)nethoxy)-3H-purin-6(7H)-one |
| 別名: |
Lingliptin impurity |
| 分子式: |
C??H??N?O? |
| 分子量: |
472.23 |
| 類別: |
Standards; Pharmaceutical/API Drug Impurities/Metabolites; |
| 應(yīng)用: |
Linagliptin Impurity, is a new potent DPP-4 inhibitor structurally derived form the xanthine scaffold for the treatment of type 2 diabetes. |
| 參考: |
|
|
|
|
|
|
